FIELD: medicine.
SUBSTANCE: solid unit dosage form with enterosoluble coating contains pharmacologically effective amount of mycophenolic acid or mycophenolate and pharmaceutically acceptable additives, where mycophenolic acid or mycophenolate are found practically in an anhydrous form in amount approximately 20 to approximately 95% on total basis of solid unit dosage form with the enterosoluble coating. There is also offered method for preparing the solid unit dosage form containing practically anhydrous mycophenolic acid or its salt.
EFFECT: high efficiency and improved storage-stability of the composition.
12 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING MYCOPHENOLIC ACID OR SALT (MYCOPHELATE) | 2002 |
|
RU2338528C2 |
| PERORAL SOLID DOSAGE FORM WITH MYCOPHENOLIC ACID OR ITS SALT FOR USE AS AN IMMUNODEPRESSANT FOR TREATMENT OR PREVENTION OF ORGAN OR TISSUE TRANSPLANT REJECTION AND METHOD FOR PRODUCTION THEREOF | 2016 |
|
RU2670447C2 |
| EXTRUDATE WITH SODIUM MYCOPHENOLATE TO PRODUCE PERORAL SOLID DOSAGE FORM | 2018 |
|
RU2723255C2 |
| PHARMACEUTICAL COMPOSITIONS BASED ON MYCOPHENOLIC ACID SALT WITH ENTEROSOLUBLE COATING | 1997 |
|
RU2203659C2 |
| PHARMACEUTICAL ENTERIC COATED COMPOSITIONS BASED ON MYCOPHENOLIC ACID SALT | 1997 |
|
RU2615397C2 |
| ORAL SUSPENSION CONTAINING HIGH DOSE OF MOFETIL MYCOPHENOLATE | 1994 |
|
RU2150942C1 |
| METHOD OF MODIFYING CRYSTALLISATION PROCESS OF MEDICINAL SUBSTANCE | 2004 |
|
RU2388757C2 |
| DOSAGE FORMS OF RISEDRONATE | 2005 |
|
RU2381791C2 |
| PHARMACOLOGICAL COMPOSITION WITH SWELLING COATING | 2004 |
|
RU2375048C2 |
| MEDICINAL FORMS ON BASIS OF BIPHOSPHONATES | 2005 |
|
RU2359678C2 |
